ATE106726T1 - Angiogenese hemmendes mittel. - Google Patents

Angiogenese hemmendes mittel.

Info

Publication number
ATE106726T1
ATE106726T1 AT89116053T AT89116053T ATE106726T1 AT E106726 T1 ATE106726 T1 AT E106726T1 AT 89116053 T AT89116053 T AT 89116053T AT 89116053 T AT89116053 T AT 89116053T AT E106726 T1 ATE106726 T1 AT E106726T1
Authority
AT
Austria
Prior art keywords
angiogenesis inhibiting
inhibiting agent
angiogenesis
prophylaxis
salts
Prior art date
Application number
AT89116053T
Other languages
English (en)
Inventor
Shoji Kishimoto
Takeshi Fujita
Tsuneo Kanamaru
Moses Judah Folkman
Donald Ingber
Original Assignee
Takeda Chemical Industries Ltd
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd, Childrens Medical Center filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE106726T1 publication Critical patent/ATE106726T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT89116053T 1988-09-01 1989-08-31 Angiogenese hemmendes mittel. ATE106726T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21928788 1988-09-01
JP5353789 1989-03-06
US39198089A 1989-08-10 1989-08-10

Publications (1)

Publication Number Publication Date
ATE106726T1 true ATE106726T1 (de) 1994-06-15

Family

ID=27294982

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89116053T ATE106726T1 (de) 1988-09-01 1989-08-31 Angiogenese hemmendes mittel.

Country Status (6)

Country Link
EP (1) EP0357061B1 (de)
KR (1) KR0141692B1 (de)
AT (1) ATE106726T1 (de)
CA (1) CA1329771C (de)
DE (1) DE68915900T2 (de)
ES (1) ES2053890T3 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
KR0138530B1 (ko) * 1988-09-01 1998-05-15 우메모또 요시마사 푸마길롤 유도체
TW282399B (de) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
ATE130517T1 (de) * 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
NZ240214A (en) 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
EP1004318A3 (de) * 1991-06-21 2002-08-07 Takeda Chemical Industries, Ltd. Zyklodextrin-zusammensetzung
US6476011B1 (en) 1991-08-28 2002-11-05 Sterix Limited Methods for introducing an estrogenic compound
US6011024A (en) 1991-08-28 2000-01-04 Imperial College Of Science Technology & Medicine Steroid sulphatase inhibitors
US6903084B2 (en) 1991-08-28 2005-06-07 Sterix Limited Steroid sulphatase inhibitors
WO1993005777A1 (fr) * 1991-09-18 1993-04-01 Fujisawa Pharmaceutical Co., Ltd. Preparation transoculaire
JPH06157344A (ja) * 1992-02-07 1994-06-03 Childrens Medical Center Corp:The 血管新生阻害のための医薬製剤及び血管新生阻害方法
EP0582459B1 (de) 1992-08-07 1998-01-07 Takeda Chemical Industries, Ltd. Herstellung von Mikrokapseln, die wasserlösliche Arzneimittel enthalten
EP0602586B1 (de) * 1992-12-16 1997-06-04 Takeda Chemical Industries, Ltd. Stabile pharmazeutische Zubereitung mit Fumagillolderivaten
US8143283B1 (en) 1993-03-01 2012-03-27 The Children's Medical Center Corporation Methods for treating blood-born tumors with thalidomide
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6114355A (en) * 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US5290887A (en) * 1993-04-30 1994-03-01 The Dow Chemical Company Epoxy resins containing thiadiazole and/or oxadiazole moieties
US5387657A (en) * 1993-09-10 1995-02-07 The Dow Chemical Company Epoxy resins containing thiadiazole and/or oxadiazole moieties
ATE198152T1 (de) * 1994-09-30 2001-01-15 Takeda Chemical Industries Ltd Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US5710148A (en) * 1995-03-06 1998-01-20 Senju Pharmaceuticals Co., Ltd. Corneal opacification inhibitory composition
US5837281A (en) 1995-03-17 1998-11-17 Takeda Chemical Industries, Ltd. Stabilized interface for iontophoresis
FR2733498B1 (fr) * 1995-04-27 1997-05-30 Adir Nouveaux composes cyclohexaniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2733499B1 (fr) * 1995-04-27 1997-05-30 Adir Nouvelles tetrahydropyrano(3,2-d)oxazolones substituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US5908400A (en) * 1996-06-20 1999-06-01 Hisamitsu Pharmaceutical Co., Inc. Device structure for iontophoresis
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
NZ336035A (en) 1996-11-05 2002-03-28 Childrens Medical Center Angiogenesis inhibitory composition comprising an inhibitory compound and antiinflammatory drug
US6673828B1 (en) 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
KR100357542B1 (ko) * 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
KR100357541B1 (ko) * 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
JP4414517B2 (ja) 1999-09-01 2010-02-10 久光製薬株式会社 イオントフォレーシス用デバイス構造体
US7335650B2 (en) 2000-01-14 2008-02-26 Sterix Limited Composition
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US6919307B2 (en) 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US7105482B2 (en) 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
BR0115109A (pt) 2000-11-01 2005-10-18 Praecis Pharm Inc Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
AU2002253795B2 (en) 2000-11-30 2007-02-01 The Children's Medical Center Corporation Synthesis of 4-Amino-Thalidomide enantiomers
EP1436286B1 (de) * 2001-09-27 2009-08-19 Equispharm Co., Ltd. Fumagillolderivate und verfahren zu deren herstellung
KR100455900B1 (ko) * 2001-09-27 2004-11-12 주식회사 아이디알 새로운 푸마질롤 유도체 및 그의 제조방법
FR2832149B1 (fr) * 2001-11-09 2006-01-06 Galderma Res & Dev Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique
US6803382B2 (en) 2001-11-09 2004-10-12 Galderma Research & Development, S.N.C. Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
AU2018270112A1 (en) 2017-05-18 2019-12-12 Tesaro, Inc. Combination therapies for treating cancer
EP3697442A4 (de) 2017-09-30 2021-07-07 Tesaro, Inc. Kombinationstherapien zur behandlung von krebs
SG11202002499TA (en) 2017-10-06 2020-04-29 Tesaro Inc Combination therapies and uses thereof
WO2019118612A1 (en) * 2017-12-12 2019-06-20 Zafgen, Inc. Targeting compounds
CN118871428A (zh) * 2022-02-16 2024-10-29 耶路撒冷希伯来大学伊森姆研究发展有限公司 Metap2抑制剂及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1333363C (en) * 1988-01-19 1994-12-06 Judah Folkman Angiogenesis inhibitor comprising fumagillin

Also Published As

Publication number Publication date
KR0141692B1 (ko) 1998-06-01
EP0357061B1 (de) 1994-06-08
CA1329771C (en) 1994-05-24
ES2053890T3 (es) 1994-08-01
EP0357061A1 (de) 1990-03-07
DE68915900T2 (de) 1994-11-24
KR900004333A (ko) 1990-04-12
DE68915900D1 (de) 1994-07-14

Similar Documents

Publication Publication Date Title
ATE106726T1 (de) Angiogenese hemmendes mittel.
NO942641L (no) Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav
NO912758L (no) Anvendelse av det virksomme stoffet flupirtin for bekjempelse av muskelspenninger.
DE68929460D1 (de) Substituierte Phenylpyrimidine Derivate, für die Behandlung oder Prevention von ZNS-Erkrankungen
ATE69376T1 (de) Haarwuchsmittel.
SE8503680D0 (sv) Indolderivat
DK249389A (da) 2-acylamino-benzothiazol-forbindelser og deres anvendelse til fremstilling af laegemidler til behandling af tumorer
DE68907423D1 (de) Behandlung der akne.
DK130387D0 (da) Transglutaminase inhibitorer
DK599789D0 (da) 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,3,4-thiadazoler og -oxadiazoler samt 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,2,4-thiadazoler, -oxadiazoler og -triazoler som anti-inflammatoriske midler
NO160369C (no) Analogifremgangsmaate for fremstilling av nye, terapeutiskaktive 1,3-dihydro-6-(1-hydroksy-2-dimetylaminometyl-allyl)-7-hydroksy-furo(3,4-c)-pyridinderivater.
DE69010162D1 (de) Zusammensetzung zur Behandlung von Entzündung.
NO170886C (no) Analogifremgangsmaate for fremstilling av nye terapeutisk aktive benzotiofener
ATE91625T1 (de) Verwendung von porphyrinderivaten bei der entdeckung und behandlung von tumoren.
ATE81004T1 (de) Laktamimide in der behandlung arzneiresistenter protozoeninjektionen.
DK23289A (da) Disubstituerede pyridinderivater, fremgangsmaade og mellemprodukter til deres fremstilling samt deres anvendelse
ATE87204T1 (de) Anti-retrovirales arzneimittel.
DE69024060D1 (de) Osteogenesis-stimulierende mittel.
DE3582935D1 (de) Mittel zur behandlung von erkrankungen der venen und des analbereichs.
ATE132039T1 (de) Verwendung von steroidderivaten zur behandlung der endometriose
DE69032000D1 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
NO873835D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive karbocykliske pyridiner.
ATE75399T1 (de) Therapeutikum zur behandlung von magengeschwueren.
ES2160102T3 (es) Tratamiento del eritema provocado por uv.
NO890245L (no) Isoxazoler med nootrop aktivitet.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
EELA Cancelled due to lapse of time